AP Pharma Inc /de/
AP Pharma Inc /de/ is listed today as Heron Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2023 | $30 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Jul 2012 | $54 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Jul 2011 | $24 M | A long-registered or listed company | $10 to $50 million | equity, options | SEC | |
| Oct 2009 | $8 M | A long-registered or listed company | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Heron Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: CINVANTI $96.76 million (62%), ZYNRELEF $38.07 million (25%), APONVIE $11.57 million (7%), SUSTOL $8.50 million (5%).
Annual report (SEC XBRL) · Dec 2025
AP Pharma Inc /de/ chose not to state its revenue in its newest notice of a funding round (Aug 2023).
SEC Form D · Aug 2023
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Aug 2023
Products and services#
No products or services of AP Pharma Inc /de/ are on record.
Investors#
No investor of AP Pharma Inc /de/ is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Heron Therapeutics, Inc. shares, as of Sep 30, 2026.
- Rubric Capital Management LP$9 M15.79%
- Clearline Capital LP$3 M5.80%
- BlackRock, Inc.$3 M5.16%
- Tang Capital Management LLC$3 M4.71%
- Velan Capital Investment Management LP$3 M4.60%
- Vanguard Capital Management LLC$2 M4.11%
- Tejara Capital Ltd$2 M3.41%
- Gsa Capital Partners LLP$2 M2.88%
- Geode Capital Management, LLC$1 M2.16%
- State Street Corp$1 M1.68%
- UBS Group AG$1 M1.11%
- AQR Capital Management LLC$1 M1.04%
- Renaissance Technologies LLC$0 M0.82%
- Millennium Management LLC$0 M0.77%
- Caption Management, LLC$0 M0.73%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Craig Collard | Executive officer | Aug 2023 |
| Ira Duarte | Executive officer | Aug 2023 |
| John B. Whelan | Executive officer | Aug 2012 |
| Michael A. Adam | Executive officer | Aug 2012 |
| Thomas A. Ottoboni | Executive officer | Aug 2012 |
| John A. Barr | Executive officer | Jul 2011 |
| John Barr | SVP, Research and Development | Nov 2009 |
| John Whelan | VP Finance and Chief Financial Officer | Nov 2009 |
| Ronald Prentki | President and Chief Executive Officer | Nov 2009 |
| Adam Morgan | Director | Aug 2023 |
| Christian Waage | Director | Aug 2023 |
| Craig Collard | Director | Aug 2023 |
| Craig Johnson | Director | Aug 2023 |
| Kevin Kotler | Director | Aug 2023 |
| Sharmila Dissanaike | Director | Aug 2023 |
| Susan Rodriguez | Director | Aug 2023 |
| Barry D. Quart | Director | Aug 2012 |
| John B. Whelan | Director | Aug 2012 |
| Kevin C. Tang | Director | Aug 2012 |
| Robert R. Rosen | Director | Aug 2012 |
| Stephen R. Davis | Director | Aug 2012 |
| Gregory C. Turnbull | Director | Jul 2011 |
| Paul A. Goddard | Director | Jul 2011 |
| Gregory Turnbull | Director | Nov 2009 |
| Kevin Tang | Director | Nov 2009 |
| Paul Goddard | Director | Nov 2009 |
| Robert Zerbe | Director | Nov 2009 |
| Ronald Prentki | President and Chief Executive Officer | Nov 2009 |
| Toby Rosenblatt | Director | Nov 2009 |
Went public since 2011. Its SEC number is that of a company listed on a stock exchange.